Αποτελέσματα Αναζήτησης
25 Οκτ 2024 · Chimeric Antigen Receptor (CAR)-T-cell therapy has revolutionized cancer immune therapy. However, challenges remain including increasing efficacy, reducing adverse events and increasing accessibility.
24 Οκτ 2024 · In an early demonstration of the use of gene-editing therapy, reported in 2021, in vivo liver-directed CRISPR-Cas9 treatment substantially reduced serum transthyretin concentrations in a small ...
10 Απρ 2017 · Therapeutic gene editing can be administered through two basic strategies: (1) direct in vivo delivery of a gene-editing nuclease and (2) delivery of cells engineered ex vivo to contain a...
1 Ιουλ 2024 · The purpose of this paper is three-fold: first, a chronological description of the history of CRISPR-Cas9-sgRNA-based gene editing; second, a brief description of the current state of clinical research in hematologic diseases, including selected applications in treating hematologic diseases with CRISPR-based gene therapy, preceded by a brief ...
CRISPR 2.0: a new wave of gene editors heads for clinical trials. Landmark approval of the first CRISPR therapy paves the way for treatments based on more efficient and more precise genome...
30 Απρ 2024 · The development of new PE variants holds significant promise for improving therapeutic gene editing by increasing editing efficiency, expanding targeting range, reducing off-target effects, multiplexing editing capability, enhancing delivery systems, and reducing immunogenicity.
The prospect of efficiently creating tailored changes to a gene of interest is revolutionizing biomedical research, allowing exciting new questions to be asked.
